MediWound (MDWD) EVP Meyer Yaron files Form 3 on equity holdings
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
MediWound Ltd. executive Meyer Yaron, EVP, General Counsel and Corporate Secretary, filed an initial Form 3 reporting his beneficial ownership in ordinary shares and stock options of MDWD.
The filing lists several stock option grants to buy ordinary shares, including options over 2,857 underlying shares at an exercise price of 36.0500 expiring on December 31, 2028, and 4,919 underlying shares at 12.2500 expiring on April 23, 2030. Additional grants cover 2,769 underlying shares at 37.5200 expiring on March 4, 2031, 9,230 underlying shares at 14.4200 expiring on May 16, 2032, and further awards expiring through 2036.
Yaron also reports direct holdings of ordinary shares tied to restricted stock units (RSUs). Footnotes explain RSU and option grants made on February 15, 2023, February 26, 2024, February 11, 2025, and March 4, 2026, each vesting 25% on the one-year anniversary of grant and 6.25% quarterly thereafter until fully vested after four years.
Positive
- None.
Negative
- None.
Insider Trade Summary
13 transactions reported
Mixed
13 txns
Insider
Meyer Yaron
Role
EVP, GC & Corp. Secretary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Ordinary shares | -- | -- | -- |
| holding | Ordinary shares | -- | -- | -- |
| holding | Ordinary shares | -- | -- | -- |
| holding | Ordinary shares | -- | -- | -- |
| holding | Ordinary shares | -- | -- | -- |
Holdings After Transaction:
Stock Option (right to buy ordinary shares) — 2,857 shares (Direct);
Ordinary shares — 1,413 shares (Direct)
Footnotes (1)
- The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on February 15, 2023 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date. The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on February 26, 2024 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date. The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on February 11, 2025 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date. The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on March 4, 2026 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date. The options reported in this row were granted to the Reporting Person on May 16, 2022 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date. The options reported in this row were granted to the Reporting Person on February 15, 2023 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date. The options reported in this row were granted to the Reporting Person on February 26, 2024 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date. The options reported in this row were granted to the Reporting Person on February 11, 2025 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date. The options reported in this row were granted to the Reporting Person on March 4, 2026 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
FAQ
What does Meyer Yaron’s Form 3 report for MediWound (MDWD)?
The Form 3 reports initial beneficial ownership for executive Meyer Yaron at MediWound. It lists his direct holdings of ordinary shares plus multiple stock option and RSU grants, detailing exercise prices, expiration dates, and four-year vesting schedules for each award.
Which stock options are disclosed for Meyer Yaron in MDWD?
The filing discloses several stock option grants to buy MediWound ordinary shares, including 2,857 underlying shares at 36.0500 expiring December 31, 2028 and 4,919 underlying shares at 12.2500 expiring April 23, 2030, plus additional grants expiring through 2036.
How do Meyer Yaron’s MediWound RSUs vest over time?
The RSUs for Meyer Yaron vest over four years. For each grant, 25% of RSUs vest on the one-year anniversary of the grant date, then 6.25% of the RSUs vest quarterly over the next three years until fully vested at the four-year mark.
Which grant dates are referenced in MDWD’s Form 3 footnotes?
Footnotes reference equity grants on February 15, 2023, February 26, 2024, February 11, 2025, and March 4, 2026. They describe RSU and option awards to Meyer Yaron, including identical 25% first-year and 6.25% quarterly vesting schedules over four years.
Does the MediWound Form 3 show any stock purchases or sales by Meyer Yaron?
The Form 3 presents holding entries only, not open-market purchases or sales. It describes existing ordinary share, option, and RSU positions for Meyer Yaron, with 13 holding entries categorized and no transactions marked as buys, sells, exercises, gifts, or tax-withholding.